Correlation Between Arcus Biosciences and Karyopharm Therapeutics

Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Karyopharm Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Karyopharm Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arcus Biosciences and Karyopharm Therapeutics, you can compare the effects of market volatilities on Arcus Biosciences and Karyopharm Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Karyopharm Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Karyopharm Therapeutics.

Diversification Opportunities for Arcus Biosciences and Karyopharm Therapeutics

0.13

Correlation Coefficient

Arcus Biosciences  Karyopharm Therapeutics

Average diversification

The 3 months correlation between Arcus and Karyopharm is 0.13. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Karyopharm Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Karyopharm Therapeutics and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Karyopharm Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Karyopharm Therapeutics has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Karyopharm Therapeutics go up and down completely randomly.

Pair Corralation between Arcus Biosciences and Karyopharm Therapeutics

Given the investment horizon of 90 days Arcus Biosciences is expected to generate 14.21 times less return on investment than Karyopharm Therapeutics. But when comparing it to its historical volatility, Arcus Biosciences is 1.46 times less risky than Karyopharm Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Karyopharm Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  71.00  in Karyopharm Therapeutics on September 4, 2024 and sell it today you would earn a total of  12.00  from holding Karyopharm Therapeutics or generate 16.9% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Arcus Biosciences  vs.  Karyopharm Therapeutics

Arcus Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Arcus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Arcus Biosciences is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Karyopharm Therapeutics

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Karyopharm Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Karyopharm Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Arcus Biosciences and Karyopharm Therapeutics

The main advantage of trading using opposite Arcus Biosciences and Karyopharm Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Karyopharm Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Karyopharm Therapeutics will offset losses from the drop in Karyopharm Therapeutics' long position.

The idea behind Arcus Biosciences and Karyopharm Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.